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We conducted the present study to evaluate the frequency and prognostic importance on long-term survival of TP53 mutations and
TP53 protein accumulation in a cohort of 178 patients with early-stage ovarian carcinomas. TP53 mutations scored as aberrant
temporal temperature gradient gel electrophoresis pattern from all exons were observed in 39.9% of the tumours. Full screening of
exons 5–8, followed by sequencing, was successful in 135 cases, and 48 mutations altering the protein were detected in 39 cases
(28.9%). TP53 mutations were slightly less common in the Federation of Gynecologists and Obstetricians stage IA than in IB/IC
(P¼0.05). No significant correlations with histological type, grade of differentiation, DNA ploidy status or age at diagnosis were
found. TP53 protein accumulation analysed by immunohistochemistry was found in 32.6% of all tumours, and was a poor predictor of
TP53 mutations with 56.4% sensitivity, 77.1% specificity, 50% positive predictive value and 81.3% negative predictive value. Neither
TP53 mutations nor TP53 protein accumulation influenced the prognosis significantly in this group of patients.
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Ovarian cancer is associated with the highest mortality rate among
gynecologic malignancies. The ovaries have a relatively inacces-
sible location and ovarian cancer patients very often lack
symptoms in early stages. Around 70% of the cases are diagnosed
at advanced stages of the disease, with either regional or distant
metastasis. No efficient screening methods are available and our
understanding of the underlying biology of the disease is still
sparse. For patients diagnosed in Norway between 1989 and 1993,
the 5-year relative survival rate was 37% for all cases and 78% for
patients diagnosed with early stages of this disease (Bjorge et al,
1998). Despite progress in surgical and chemotherapy treatment,
no major improvement in the long-term survival has been
achieved. The genetic mechanisms contributing to the develop-
ment and progression of epithelial ovarian cancer are not well
understood, and the lack of good prognostic markers has led to
several studies aiming at identifying new molecular markers with
both predictive and prognostic value.
The TP53 tumour-suppressor gene is frequently mutated in
human cancer, and has been shown to be a prognostic marker in
several tumour types (Hollstein et al, 1991; Borresen-Dale, 2003;
Iacopetta, 2003). The gene is located on the short arm of
chromosome 17, at position 17p13.1, and encodes a 53kDa
nuclear phosphoprotein whose regulatory actions include both
the inhibition and stimulation of transcription (Levine et al, 1991).
The TP53 protein acts as a checkpoint control for recognising
damaged DNA, allowing DNA repair and delayed entrance into the
DNA-replication phase of the cell cycle. When DNA repair is not
possible, programmed cell death or apoptosis follows. The loss of
tumour-suppressor function of the TP53 protein, subsequent to a
mutation in the coding sequence, seems to be a feature common to
many cancers, including ovarian cancer. The primary mechanism
of this dysfunction in ovarian cancer is a missense mutation in the
evolutionary conserved domains of the gene. However, microdele-
tions, insertions and nonsense mutations have also been described
(Sood et al, 1999; Buller et al, 2001). A number of studies have
analysed ovarian carcinomas for TP53 mutations, but mostly in
advanced stages (Kohler et al, 1993; Kupryjanczyk et al, 1993,
1995; Fallows et al, 2001; Reles et al, 2001; Leitao et al, 2002). The
frequency of mutations was reported to be in the range of 29–79%
depending on the stage of the disease, with the highest frequency
found in tumours from patients diagnosed with late-stage disease.
The impact of TP53 alterations on prognosis in patients with
ovarian cancer has also been studied, but again mainly focused on
advanced disease. The majority of studies demonstrated that TP53
alterations failed to influence the prognosis in multivariate analysis
including known prognostic factors (Wen et al, 1999; Schildkraut
et al, 2000; Fallows et al, 2001). Only few studies have focused on
the early stage of ovarian carcinomas, and these have indicated
that TP53 alteration may be an early genetic event occurring before
metastasis (Kohler et al, 1993; Kupryjanczyk et al, 1995). The
number of samples studied has, however, been limited and the
follow-up time relatively short. This study reports TP53 mutations
and TP53 protein expression among 178 patients with early-stage
ovarian carcinomas, in order to evaluate the prognostic signifi-
cance of TP53 alterations on long-term survival. Revised 9 September 2003; accepted 5 November 2003
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Patient population and clinical data
The study population consisted of a total of 178 patients with
early-stage ovarian carcinomas, who were treated at the Depart-
ment of Gynecological Oncology at The Norwegian Radium
Hospital (NRH) during the period 1982–1989. Generally, surgery
was performed at county hospitals and the patients were admitted
to NRH for evaluation of further treatment. The surgical procedure
consisted of a midline incision with peritoneal washing, hyster-
ectomy, bilateral salpingo-oophorectomy, omentectomy and
throughout inspection of the abdominal cavity. Lymph node
sampling was not performed. In all patients, the tumours were
restricted to one or both ovaries by these evaluations, and thereby
apparently in the International Federation of Gynecologists and
Obstetricians (FIGO) stage I. All tissue removed at surgery was
immediately fixated in buffered formalin and processed at the
Department for Pathology within 24–72h. One single pathologist
at NRH reviewed all histological sections. The histological type and
grade of differentiation were based on World Health Organization
criteria. All, but eight patients, had adjuvant treatment following
surgery, 90 had chemotherapy (76 cisplatinum as a single drug and
14 thiotepa), 63 had intraperitoneal instillation of
32P, 15 had
whole abdominal external radiation, while two patients had other
types of treatment.
All patients have been followed up at the NRH or at local
hospitals until death or December 31, 1999. Follow-up of patients
alive without relapse ranged from 10 to 17 years, with a median
follow-up of 13.9 years. Patient’s age ranged from 15 to 83 years,
with a median age of 57.8 years. The clinical and histopathological
characteristics of the patients are summarised in Table 1. DNA
ploidy analysis was performed with a high-resolution image
system, as previously described (Sudbo et al, 2001).
Mutation analyses
Haematoxylin—Eosin-stained sections were used to evaluate the
approximate percentage of tumour tissue. All samples contained
20% or more tumour tissue. DNA was isolated from paraffin-
embedded ovarian carcinoma tissues by phenol/chloroform
extraction, followed by ethanol precipitation. Amplification of
exons 2–11 of the TP53 gene was performed by the polymerase
chain reaction (PCR), followed by temporal temperature gradient
gel electrophoresis (TTGE) analyses. All samples with aberrantly
migrating bands in exons 5–8 were submitted to direct sequencing
of a new PCR product using standard dideoxy sequencing reaction
and the Dye Terminator Cycle Sequencing kit with AmpliTaq FS,
and analysed on an ABI 373 sequencer (Applied Biosystems). The
primer sets and condition for TTGE and sequencing were as
previously described (Srlie et al, 2003).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue specimens were used for
immunohistochemical staining with the avidin–biotin–peroxidase
complex (ABC) method, as previously described (Hsu et al, 1981).
Table 1 Clinicopathologic parameters in relation to TP53 status
All exons
a Exons 5–8
b
Variable Total mut (%) P Total mut (%) P IHC(%) P
Total 178 71 (39.9) 135 39 (28.9) 44 (32.6)
Age 0.23 0.97 0.51
p60 years 100 36 (36) 73 21 (28.8) 22 (30.1)
460 years 78 35 (44.5) 62 18 (29.0) 22 (35.5)
Histological type 0.57 0.77 0.002
c
Serous 37 16 (43.2) 30 9 (30) 15 (50)
Mucinous 47 16 (34) 35 10 (28.6) 10 (28.6)
Endometriod 35 16 (45.7) 25 9 (36) 7 (28)
Clear cell 32 11 (34.4) 24 5 (20.8) 4 (16.7)
Mixed with CCC 7 2 (28.6) 7 2 (28.6) 2 (28.6)
Mixed without CCC 6 2 (33.3) 5 1 (20) 1 (20)
Unclassified 12 6 (50) 8 2 (25) 5 (62.5)
Small cell 2 2 (100) 1 1 (100) 0 (0)
Grade of differentiation 0.7 0.48 o0.001
Well 72 28 (38.9) 54 16 (29.6) 10 (18.5)
Moderate 30 13 (43.3) 22 5 (22.7) 7 (31.8)
Poor 37 17 (45.9) 28 11 (39.3) 21 (75)
Not stated
d 39 13 (33.3) 31 7 (22.6) 6 (19.4)
FIGO stage 0.7 0.05
e 0.3
e
IA 63 27 (42.9) 48 9 (18.8) 13 (27.1)
IB 13 4 (30.8) 10 3 (30) 4 (40)
IC 102 40 (39.2) 77 27 (35.1) 27 (35.1)
Image ploidy analysis 0.17
f 0.11
f 0.01
f
Diploid/tetraploid 102 37 (36.3) 69 16 (23.2) 16 (23.2)
Aneuploid/polyploid 66 31 (47) 58 21 (36.2) 27 (46.6)
Not done 10 3 (30) 8 2 (25) 1 (12.5)
CCC¼clear cell component; mut¼TP53 mutation; IHC¼TP53 protein accumulation by IHC.
aMutations scored as aberrant by TTGE shifts.
bOnly samples where exons 5–8
were successfully analysed and mutations scored as sequence alterations leading to altered protein were included.
cSerous and unclassified compared with all other types.
dGrade
of differentiation was not stated for the clear cell carcinoma or for mixed tumours with clear cell components.
eFIGO stage IA compared with stages IB and IC.
fDiploid/tetraploid
compared with aneuploid/poliploid.
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6.0, to unmask the epitopes of TP53 proteins. Then, the sections
were incubated for 18–22h in 41C with the polyclonal TP53
antiserum (NCL-CM1, Novocastra laboratory Ltd, UK), diluted
1:2000, and monoclonal antibodies TP53 (DO-1, Santa Cruz
Biotechnology Inc., CA, USA) diluted 1:1000 (1mg IGg2aml
 1).
Both TP53 antibodies detected mutant and wild-type TP53 protein.
The sections were incubated with a biotin-labelled secondary
antibody and avidin–biotin–peroxidase complex. The peroxidase
reaction was developed using diaminobenzidine as chromogen. All
series included replacement of polyclonal primary antiserum with
normal rabbit serum diluted 1:2000, whereas negative controls for
the monoclonal antibody were performed using mouse myeloma
protein of the same subclass and concentration as the monoclonal
antibody. All controls gave satisfactory results. The results of the
immunohistochemical analysis were interpreted without knowl-
edge of the clinical information or mutation status using TTGE
analyses. Three semiquantitative classes were used to describe the
number of immunostained cells:  , none or less than 10% of the
cells; þ, 10–50% of the cancer cells; and þþ, more than 50% of
the cells. The tumours with more than 10% immunostained cells in
either of the two TP53 antibodies (NCL-CM1 and DO-1) were
defined to have TP53 protein accumulation. A section from a
breast carcinoma with TP53 mutation was used as a positive
immunohistochemical control.
Statistics
Differences in proportions were evaluated by the w
2 test. Disease-
free survival was defined as the time interval between diagnosis
and relapse of ovarian cancer. The method of Kaplan and Meier
and the log-rank test were used to estimate and compare survival
rates. Independent prognostic factors were determined by Cox
proportion hazards analysis. Statistical significance was considered
as Po0.05.
RESULTS
TP53 mutation frequency
A total of 178 primary early-stage ovarian carcinomas were
analysed for TP53 mutations in exons 2–11 using the TTGE
methodology. Mutations scored as an aberrant TTGE pattern were
seen in 71 cases (39.9%), with 75% of the mutations located in
exons 5–8. Several samples had more than one mutation and a
total of 91 aberrant TTGE patterns were observed. This frequency
may be an underestimate, since not all exons gave a PCR product
that could be analysed by TTGE. Success rate in obtaining a clean
and analysable PCR product ranged from 25.3 to 97.8%, with the
lowest success rate for exons 4 and 10. Samples with mutations
found in exons 2–4 and 9–11 by TTGE were not submitted to
sequencing, due to limited amount of mutations in most of these
exons and problems with PCR amplification due to the limited
amount of DNA. Exons 5–8 were successfully analysed for a total
of 135 samples by TTGE, followed by sequencing of all samples
with aberrant migrating bands on TTGE, and a total of 65 TP53
alterations were detected in 53 out of 135 (39.3%) samples by
TTGE.
Spectrum of TP53 mutations in exons 5–8 by direct
sequencing
The exact sequence alterations were successfully determined by
direct sequencing in 59 of the cases representing 47 different
patients (Table 2). An example of a TTGE analysis followed by
sequencing is shown in Figure 1A–C. Of the 59 mutations
detected, nine were silent mutations, with none being common
polymorphisms. Two were intronic mutations with unknown
function, leaving a total of 48 mutations altering the TP53 protein
in 39 different patients (28.9%). Seven patients revealed two
different mutations and one had three different mutations. The
mutations were distributed throughout the four exons examined,
with 21 in exon 5, nine in exon 6, 17 in exon 7 and 18 in exon 8
(Figure 2A and B). The majority of the sequenced mutations in this
region, 56 of 59 (94.9%), was point mutations. In all, 44 (75%) of
the mutations were missense with one sample having two base
changes in the same codon (No. 308). Two samples had a deletion
consisting of the same single base pair loss (no. 329; no. 378),
leading to a frameshift mutation, and one sample (no. 363) had a
12 base pair deletion in exon 5, leading to an in-frame mutation.
The majority of the point mutations appeared at G:C base pairs
(46 of 56, 82.1%), of which 11 were at CpG dinucleotides, and
G:C-A:T transitions accounted for 64.3% (36 of 56). Totally,
there were 75% transitions and 25% transversions. In all, 17 of the
mutations disrupted the loop 2 or loop 3 domains of TP53 protein.
Mutations in codons 146, 152, 187, 200, 204, 225 and 301 have not
previously been reported in the International Agency for Research
on Cancer (IARC) TP53 mutation database (http://www.iarc.fr/
P53/index.html.2002) among ovarian cancers. The comparisons of
exon and codon distributions with IARC TP53 mutation database
are shown in Figure 2A and B.
Immunohistochemistry
Considering the 135 samples where all exons 5–8 were successfully
analysed by TTGE followed by sequencing, 44 samples (32.6%)
demonstrated TP53 protein accumulation by IHC, with 27 samples
showing immunostaining in more than 50 percent of the tumour
cells and 17 samples in 10–50% of the cells. The correlation
between TP53 protein accumulation and TP53 mutations was
significant (Po0.001); however, the concordance was only 71.1%
(96 of 135). The sensitivity, specificity, positive and negative
predictive values of IHC analysis of TP53 protein accumulation in
predicting for TP53 mutations were 56.4, 77.1, 50 and 81.3%,
respectively.
TP53 mutations and clinicopathological parameters
The relationship between TP53 mutations and clinicopathological
parameters is shown in Table 1. TP53 mutation status was not
significantly correlated with age at diagnosis, histological type,
grade of differentiation or DNA ploidy status. However, there
seemed to be a trend towards TP53 mutations being less common
in FIGO stage IA than in IB/IC (P¼0.05). TP53 protein
accumulation was significantly correlated with the grade of
differentiation and DNA ploidy status, but not with FIGO stage
or age at diagnose. TP53 protein accumulation was significantly
more common in serous and unclassified than in other histological
types (Table 1).
Relationship between TP53 mutations and survival
Kaplan–Meier analyses of disease-free survival in all 178 patients
showed no difference between patients with and without TP53
mutations scored as a TTGE shift, the 5-year survival rates being
66 and 81%, respectively (P¼0.1). Furthermore, no significant
difference was found between patients with or without TP53
protein accumulation by IHC, the 5-year survival rates being 69
and 78%, respectively (P¼0.2). When considering the 135 samples
with complete analyses of exons 5–8, there was no significant
difference in disease-free survival between patients with or without
TP53 mutations affecting the protein (Figure 3A). When samples
with mutations affecting the L2/L3 loop of the protein were
grouped separately, there was still no difference in survival rates
(Figure 3B). When considering TP53 mutations and TP53 protein
accumulation as TP53 aberrances, the 5-year survival rate was 80%
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yTable 2 Characterization of the TP53 alterations found in exons 5–8 in this series
Case Exon Codon Sequence change Nucleotide change Amino-acid change Type of mutation Effect on protein IHC
192 5 132 AAG4AATG : C 4T:A Lys4Asn mis. ++
333
a 5 138 GCC4GTC G:C4A:T Ala4Val mis.  
344 5 141 TGC4TAC G:C4A:T Cys4Tyr mis.  
22
a 5 152 CCG4CTG G:C4A:T Pro4Leu mis.
b  
314 5 152 CCG4CTG G:C4A:T Pro4Leu mis.
b +
382
a 5 156 CGC4TGC G:C4A:T Arg4Cys mis.
b +
22
a 5 157 GTC4ATC G:C4A:T Val4Ile mis.  
302 5 162 ATC4GTC A:T4G:C Ile4Val mis. ++
300 5 163 TAC4TGC A:T4G:C Tyr4Cys mis. L2 ++
333
a 5 168 CAC4TAC G:C4A:T His4Tyr mis. L2  
382
a 6 187 GGT4AGT G:C4A:T Gly4Ser mis. L2 +
356 6 190 CCT4TCT G:C4A:T Pro4Ser mis. L2  
298
c 6 200 AAT4GAT A:T4G:C Asn4Asp mis.  
298
c 6 204 GAG4AAG G:C4A:T Glu4Lys mis.  
252 6 215 AGT4TGT A:T4T:A Ser4Cys mis.  
180
a 6 220 TAT4TGT A:T4G:C Tyr4Cys mis. ++
254
a 7 225 GTT4ATT G:C4A:T Val4Ile mis.  
297 7 236 ATG4ATCG : C 4C:G Met4Ile mis. L3 ++
308
a 7 237 ATG4ATAG : C 4A:T Met4Ile mis. L3  
310 7 237 ATG4ATAG : C 4A:T Met4Ile mis. L3  
131 7 241 TCC4TGC G:C4C:G Ser4Cys mis. L3 ++
101 7 243 ATG4ATAG : C 4A:T Met4Ile mis. L3  
359 7 244 GGC4GTC G:C4T:A Gly4Val mis. L3 +
370 7 244 GGC4GTC G:C4T:A Gly4Val mis. L3  
13 7 249 AGG4AGTG : C 4T:A Arg4Ser mis. L3 ++
31 7 249 AGG4ACG G:C4C:G Arg4Thr mis. L3 +
365 8 265 CTG4CCG A:T4G:C Leu4Pro mis.  
80 8 266 GGA4GAA G:C4A:T Gly4Glu mis. ++
367 8 266 GGA4GAA G:C4A:T Gly4Glu mis.  
286
a 8 271 GAG4GACG : C 4C:G Glu 4Asp mis.  
123 8 272 GTG4ATG G:C4A:T Val4Met mis.  
227
a 8 273 CGT4CAT G:C4A:T Arg4His mis.
b ++
259
a 8 273 CGT4CAT G:C4A:T Arg4His mis.
b ++
264 8 273 CGT4CAT G:C4A:T Arg4His mis.
b ++
295 8 273 CGT4CAT G:C4A:T Arg4His mis.
b +
301 8 273 CGT4CAT G:C4A:T Arg4His mis.
b +
308
a 8 273 CGT4CAG G:C4A:T, A:T4C:G Arg4Gln mis.
b  
330 8 275 TGT4TAT G:C4A:T Cys4Tyr mis.  
366 8 275 TGT4TTT G:C4T:A Cys4Phe mis. ++
14
a 8 282 CGG4TGG G:C4A:T Arg4Trp mis.
b ++
14
a 8 283 CGC4CTC G:C4T:A Arg4Leu mis.
b ++
259
a 8 297 CAC4TAC G:C4A:T His4Tyr mis. ++
227
a 8 298 GAG4AAG G:C4A:T Glu4Lys mis. ++
78 8 301 CCA4TCA G:C4A:T Pro4Ser mis. +
298
c 5 146 TGG4TGAG : C 4A:T Trp4Stop non. L2  
363 5 175–178 del GCTGCCCCCACC del. (in-frame) L2 ++
329 7 241 722 del C stop codon 246 TGA del. (fram.) L3  
378 7 241 722 del C stop codon 246 TGA del. (fram.) L3 ++
500 6 559  6C4T Intronic variation  
182 7 783+15C4T Intronic variation  
326 5 131 AAC4AATG : C 4A:T Asn4Asn sil.  
285 5 137 CTG4TTG G:C4A:T Leu4Leu sil. +
180
a 5 147 GTT4GTA A:T4T:A Val4Val sil. ++
286
a 5 155 ACC4ACTG : C 4A:T Thr4Thr sil.  
173 5 159 GCC4GCTG : C 4A:T Ala4Ala sil. ++
290 6 200 AAT4AAC A:T4G:C Asn4Asn sil.  
387 7 232 ATC4ATTG : C 4A:T Ile4Ile sil.  
35 7 234 TAC4TATG : C 4A:T Tyr4Tyr sil. +
254
a 7 253 ACC4ACTG : C 4A:T Thr4Thr sil.  
95 M from TTGE +
226 5 M from TTGE ++
323 5 M from TTGE +
377 5 M from TTGE  
289 6 M from TTGE  
282 7 M from TTGE  
mis.¼missense; sil.¼silent mutation; non.¼nonsense mutation; fram.¼frameshift mutation; del.¼deletion; M from TTGE¼mutation from TTGE, not enough high-quality
DNA for sequence analysis. IHC:TP53 protein accumulation;  ,n oo ro10% cells with TP53 protein accumulation; +, 10–50% and ++450% cells with TP53 protein
accumulation. Effect on protein: effect of TP53 mutations on TP53 protein function. L2, L3: TP53 mutations affecting the loop 2 or loop 3 domains of the protein.
aTwo mutations
in the same sample.
bG:C4A:T transition at CpG dinucleotide.
cThree mutations in the same sample.
TP53 alterations in early-stage ovarian carcinoma
Y Wang et al
681
British Journal of Cancer (2004) 90(3), 678–685 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yfor patients with wild type and 61% for patients with TP53
aberrance, but the difference in disease-free survival was not
statistically significant (Figure 3C).
Among these 135 patients, platinum-based adjuvant chemother-
apy was given to 59 patients and adjuvant radiotherapy to 57
patients after primary operation. Analysing these two patient
groups separately did not give any difference in disease-free
survival between patients with or without TP53 mutations in any of
these groups.
DISCUSSION
TP53 has proved itself to be an important tumour-suppressor gene
frequently found inactivated in human cancers, including ovarian
carcinoma. We have analysed a large series of early-stage primary
ovarian carcinomas, and found TP53 mutations in 39.9% of the
tumours with 75% of the mutations located in exons 5–8. The
analysed cohort is unique, since it is a sizable number of early-
stage ovarian carcinomas with long-term follow-up. Some varia-
tions may be expected in sampling procedures, since the tumour
materials have been collected from different hospitals. However,
the time from fixation until the tissue reached the pathology lab
was less than 72h, and we considered this to be an acceptable
uniform handling of the tissue. All tumour samples were obtained
from primary operation before exposure to adjuvant therapy, thus
avoiding any possible contribution from exposure to DNA-
damaging agents. Among the 135 samples where exons 5–8 were
successfully analysed, 39.3% revealed TP53 mutations. This result
agrees with previous studies on smaller cohorts (Kohler et al, 1993;
Buttitta et al, 1997; Reles et al, 2001; Leitao et al, 2002), which have
shown a TP53 mutation rate in early-stage ovarian cancer between
15 and 50%. In the present study, TTGE was used, followed by
DNA direct sequencing to analyse TP53 mutations. Temporal
temperature gradient gel electrophoresis is an improved mutation-
screening technique (Borresen-Dale, 1996; Srlie et al, 2003),
which combines some advantages of the related techniques
denaturing gradient gel electrophoresis (DGGE) and constant
denaturant gel electrophoresis (CDGE), and eliminates some of the
problems. The sensitivity of TTGE in detecting mutations present
in only a small fraction of the sample is around 10% at the
homoduplex level and 1–3% at the heteroduplex level, which is
considerably better than can be achieved by direct sequencing.
Figure 1 Temporal temperature gradient gel electrophoresis and
sequence analysis on sample No. 131 with a C to G substitution at codon
241 in exon 7. (A) TTGE analyses with a mutation control in lane 1 and
sample 131 in lane 9. (B) Direct sequencing result of a normal control. (C)
Direct sequencing result of sample No. 131.
40
30
20
10
0
126 146 166 186 206 226 246 266 286 306
126 146 166 186 206 226 246 266 286 306
175
179 220
248
245
273
273
275
IARC database (n=553) (all stages)
152
244
237249 266
Our results (n=45) (early stage) 7
6
5
4
2
3
0
1
N
u
m
b
e
r
 
o
f
 
m
u
t
a
t
i
o
n
s
N
u
m
b
e
r
 
o
f
 
m
u
t
a
t
i
o
n
s
P
e
r
c
e
n
t
 
o
f
 
m
u
t
a
t
i
o
n
s
Number of codons
50
40
30
20
10
0
5678
Number of exons
Our results (n=45) (early stage)
Database (n=553) (all stages)
A
B
Figure 2 (A) Codon distribution of TP53 point mutations altering the
TP53 protein. (B) Exon distribution of TP53 point mutations altering the
TP53 protein (in percentage).
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sensitive and the result is rapid and easier to evaluate. Besides,
the most common polymorphisms of the TP53 gene (codon 72
polymorphism in exon 4 and codon 213 polymorphism in exon 6)
have specific patterns on TTGE gel, which are quite specific and
are easy to distinguish by the naked eye. None of the eight
mutations in exon 4 and the one mutation in exon 6, which could
not be confirmed by sequencing in the present study, had the
patterns of the well-known polymorphisms on the TTGE gel. Thus,
none of the samples with mutations listed in Table 1 under ‘all
exons’ are likely to carry any of the common polymorphisms.
We found no mutational hotspots in the TP53 gene in human
early-stage ovarian carcinomas, in agreement with previous
investigators (Mazars et al, 1991; Okamoto et al, 1991; Mein-
hold-Heerlein et al, 2001). The most frequent mutations were
found in codon 273 and in six samples, with one sample (No. 308)
showing mutations in two of the bases in this codon. Whether
these were two mutations on two different alleles or whether they
resided on the same allele could not be decided. A frequent
mutation in the IARC TP53 mutation database resides in codon
175. None of our samples showed this mutation. A control sample
with this mutation was successfully analysed, confirming the
negative result of this mutation in the described series. The codon
175 mutation might be a late event more common in advanced
stages. Several novel mutations, not previously reported in the
IARC TP53 mutation database in ovarian cancer, were determined.
Otherwise, the spectrum of mutations is in agreement with that
reported in the database.
Similar to the TP53 mutations reported in other types of human
cancers, the majority (94.9%) of TP53 mutations in the present
study of early-stage ovarian carcinomas were point mutations. A
low frequency of deletions was found in the present study, which is
in agreement with a previous study (Wen et al, 1999) reporting
deletions in 7% after analysing all exons of the TP53 gene in 105
ovarian carcinomas.
In a review of TP53 mutations found in ovarian cancer (Skilling
et al, 1996), it was reported that 234 of 280 mutations were
nucleotide substitutions with 157 transitions and 77 transversions.
Our finding of 75% transitions and 25% transversions is consistent
with a high frequency of transitions in ovarian carcinoma, and the
most common base substitution observed was G:C4A:T. The
predominance of transition mutations suggests that TP53 muta-
tions in ovarian carcinomas arise because of spontaneous errors in
DNA synthesis and repair, rather than the direct interaction of
carcinogens with DNA.
One of the features of the TP53 mutational spectra in human
cancer is that transition at CpG dinucleotides contributes heavily
to the mutation frequency in many cancers. However, in the
present study, transitions at CpG sites were found only in
11(19.6%) of the 56 point mutations. This is significantly lower
than that found among colon carcinomas (67%) (Rodrigues et al,
1990), but is in agreement with previous observations that
transitions at CpG dinucleotides are not frequent in ovarian
cancer (Hollstein et al, 1991). This indicates that methylation of
CpG sites and the level of spontaneous deamination may differ in
various tissue types.
A few studies have described both TP53 mutation status and
protein expression among ovarian carcinomas (Marks et al, 1991;
Skilling et al, 1996; Wen et al, 1999). In the present study, we found
TP53 protein accumulation in 32.6% of the cases. This is in
accordance with the findings reported in the literature, which
indicate increased protein expression in 26–69% (Marks et al,
1991; Niwa et al, 1994; Skilling et al, 1996; Buttitta et al, 1997; Wen
et al, 1999; Skirnisdottir et al, 2002). Although TP53 protein
accumulation was significantly correlated with TP53 mutation in
the present study, the concordance was only 71.1%. The sensitivity,
specificity, positive and negative predictive values of IHC in
predicting for TP53 mutations were 56.4, 77.1, 50 and 81.3%,
respectively. Mutations usually lead to accumulation of mutated
protein. However, some mutations create a stop codon and hence
no protein is encoded, or some mutations do not lead to stable
proteins that can be detected by IHC. Furthermore, mechanisms
other than mutations may lead to accumulation like binding to
cellular proteins or virus proteins or accumulation after a cellular
response to DNA damage. One study (Hall et al, 1993) showed that
a substantial part of the samples (39%) without any detectable
TP53 mutations may reveal increased TP53 protein levels by
immunohistochemistry. This could reflect accumulation of normal
TP53 protein induced by interacting proteins on a replicational,
transcriptional or translational level. This means that IHC analysis
of TP53 protein accumulation is a poor predictor of TP53
mutations, and accurate assessment of TP53 mutations requires
DNA analyses.
Prognostic factors for patients with cancer are sought in order to
learn about the natural progression of disease and to predict the
outcome for individual patients. Additionally, these factors may
help identify patients for whom the failure of conventional
treatment could be predicted in advance. Although a number of
authors (Dembo et al, 1990; Vergote et al, 2001) have evaluated
traditional clinical parameters such as histology, grade, stage and
presence of ascites as predictors for poor outcome in patients with
stage I ovarian cancer, individual patient outcome is not entirely
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molecular biological features have therefore been studied in an
attempt to identify the additional factors of prognostic importance.
Some studies have looked at the prognostic significance of TP53
alteration in ovarian cancers, and addressed the possibility that the
clinical behaviour of tumours with TP53 alterations might be
significantly different from that of tumours without TP53
alterations (Kohler et al, 1993; Kupryjanczyk et al, 1995; Geisler
et al, 1997; Shahin et al, 2000; Fallows et al, 2001; Suzuki et al,
2001; Valverde et al, 2001). However, most of these studies
addressed patients with advanced stage of the disease, and
analysed relatively small numbers of tumours. In addition, TP53
protein accumulation has often been used as an indirect indicator
of mutation. Therefore, diverging results have been reported on
the prognostic significance of TP53 alterations in ovarian cancer,
especially in early stage. Some studies have shown that TP53
alterations are more frequent in serous adenocarcinoma and in
poorly differentiated tumours (Geisler et al, 1997; Leitao et al,
2002; Skirnisdottir et al, 2002), while others were not able to
demonstrate these differences (Marks et al, 1991; Fallows et al,
2001; Leitao et al, 2002). Ploidy status has previously been
demonstrated to be an independent prognostic factor among early-
stage ovarian carcinomas (Vergote et al, 1993; Valverde et al,
2001). In the present study, TP53 protein accumulation was
significantly related to DNA ploidy status, and was more often
found in serous and unclassified adenocarcinomas as well as in
poorly differentiated tumours. TP53 mutations were marginally
less common in FIGO stage IA than in IB and IC; otherwise, no
significant correlation was found to other clinicopathologic
variables. Preliminary results from a series of advanced stage of
ovarian carcinomas from our laboratory show a significant
correlation to these parameters both for TP53 protein accumula-
tion and TP53 mutations (unpublished data). These findings point
to a role for TP53 mutations in progression of the disease, and that
the changes in the TP53 gene in early stage are not sufficient for
producing a highly malignant tumour.
In the present study, we have extensive follow-up of 178 patients
with a median follow-up of 13.9 years. Although the presence of
TP53 mutations did not seem to influence the disease-free survival
significantly in early stage of ovarian carcinomas, patients with
wild-type TP53 gene had around 15% higher survival rate than
patients with mutant TP53 gene after 5 years, which is in
agreement with previous studies (Auer et al, 1996). The lack of
statistical significance has to be evaluated on the basis of the
number of the patients in the study. The different types of TP53
mutations, missense and nonmissense (nonsense, frameshift
mutation and in-frame mutation) did not influence disease-free
survival. TP53 mutations disrupting the loop 2 and loop 3 domains
of the protein have been shown to predict poor survival in breast
cancer (Borresen et al, 1995) and colorectal cancer (Borresen-Dale
et al, 1998). Wen et al (1999) studied 105 ovarian cancers, and the
overall survival for women with TP53 mutations in loop 2, loop 3
and loop–sheet–helix domains together showed a statistically
significant difference in survival compared to survival of women
whose ovarian cancers had other mutations. However, among
these 105 patients, only 17 patients were in early stages. In the
present study, the presence of TP53 mutations in loop 2 and loop 3
did not seem to influence the disease-free survival on early-stage
disease, although a 17% difference in the 3-year survival rate was
seen. Combining TP53 mutation with protein accumulation has
been found to be a stronger predictor of prognosis than TP53
mutation alone (Wen et al, 1999). This may indicate that tumour
cells with TP53 accumulation without a mutation may have altered
the TP53 pathway, resulting in a more aggressive behaviour. In the
present study, we found a similar effect, but the difference in
disease-free survival did not reach statistical significance.
Some studies have shown that loss of TP53 gene function may
contribute to the drug resistance of ovarian cancer (Righetti et al,
1996; Buttitta et al,1 9 9 7 ;M a r xet al, 1998). However, one study
showed no significant association between TP53 mutation status
and prognosis for patients who received platinum-based che-
motherapy after analysing 45 FIGO stage IIC–III ovarian carcino-
mas (Smith-Sorensen et al, 1998). Platinum-based adjuvant
chemotherapy was given to 59 out of 135 patients with complete
TP53 mutation status from exons 5 to 8 after primary operation in
the present study. However, TP53 mutation status had no significant
influence on disease-free survival when this group was analysed
separately. This disagreement could be explained by difference in
stages between our study and previous studies (Righetti et al, 1996;
Buttitta et al, 1997; Marx et al, 1998) and relative limited numbers of
patients who were given platinum-based adjuvant chemotherapy
after primary surgery in the present study.
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